Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 21 March, 2013 and appeared in  Women's HealthIssue 669

Two Glucose Uptake Mechanisms Affected by Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) poses a double impact in glucose control in women with the highest level of insulin resistance....

Advertisement

A recent study, compared 28 healthy women with 28 with PCOS showing that women with PCOS had a decrease in both insulin and non-insulin glucose controlling mechanisms. PCOS participants with the most insulin resistance at the start of the trial had results that showed a decline in their ability to compensate with non-insulin glucose controlling mechanisms.

Dr. Ricardo Azziz, reproductive endocrinologist and PCOS expert at Georgia Regents University, states, "Women with PCOS who have the highest levels of insulin resistance, the greatest difficulty controlling their sugar and the highest risk for diabetes, appear to have a double defect in how glucose is controlled, which affects both the mechanisms that use insulin and those that do not." The study measured visceral and subcutaneous fat distribution, which predicted the degree of insulin and non-insulin glucose control, respectively.

"If the fat is not as sensitive to insulin, that obviously means blood sugar levels, and probably fat and cholesterol levels as well, increase and the pancreas responds by producing more insulin," Azziz said. "Fat abnormalities can have a tremendous impact on how we feel and how we function."

In the future, the researchers want to construct a study that includes understanding the molecular mechanisms involved in how PCOS affects glucose usage.

Journal of Clinical Endocrinology & Metabolism, 2013; DOI: 10.1210/jc.2012-2937 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 21 March, 2013 and appeared in  Women's HealthIssue 669

Past five issues: Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
HbA1c Increases with Age
Posted August 01, 2014
Early Insulin Delays Diabetes But Are There Negative Consequences?
Posted August 15, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Silvia Inzucchi, MD

Category: General Diabetes
Credits: .75
Search Articles On Diabetes In Control